86408-45-9 (氮位N-脱甲基盐酸地尔硫卓,DESMETHYL DILTIAZEM HCL)

CAS号:
86408-45-9
中文名称:
氮位N-脱甲基盐酸地尔硫卓
英文名称:
DESMETHYL DILTIAZEM HCL
分子式:
C21H24N2O4S
分子量:
400.491264343262

氮位N-脱甲基盐酸地尔硫卓(86408-45-9)名称与标识符

名称

中文别名:
N-去甲地尔硫卓马来酸盐;N-去甲盐酸地尔硫卓;N-脱甲基马来酸地尔硫卓;马来酸N-去甲基地尔硫卓(1:1) 标准品;N-脱甲基地尔硫卓,马来酸D5;氮位N-脱甲基盐酸地尔硫卓;
英文别名:
DESMETHYL DILTIAZEM HCL;DESMETHYL DILTIAZEM-D4 HCL;N-Desmethyldiltiazem maleate (1:1);1,5-Benzothiazepin-4(5H)-one,3-(acetyloxy)-2,3-dihydro-2-(4-methoxyphenyl)-5-(2-(methylamino)ethyl)-,(2S,3S);desmethyldiltiazem;N-desmethyl-diltiazem;N-monodesmethyl diltiazem;(2S,3S)-3-(Acetyloxy)-2,3-dihydro-2-(4-methoxyphenyl)-5-[2-(methylamino)ethyl]-1,5-benzothiazepin-4(5H)-one (ACI);1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-2,3-dihydro-2-(4-methoxyphenyl)-5-[2-(methylamino)ethyl]-, (2S-cis)- (ZCI);N-Demethyldiltiazem;N-Desmethyldiltiazem;N-Monodesmethyldiltiazem;[(2S,3S)-2-(4-methoxyphenyl)-5-[2-(methylamino)ethyl]-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate;IF0841K5LK;DTXSID40234221;N-desmethyl Diltiazem (hydrochloride);Nordiltiazem;86408-45-9;NS00126988;desmethyl diltiazem;CHEBI:169303;N-Monodemethyldiltiazem;1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-2,3-dihydro-2-(4-methoxyphenyl)-5-(2-(methylamino)ethyl)-, (2S,3S)-;DILTIAZEM HYDROCHLORIDE IMPURITY D [EP IMPURITY];cis-3-(Acetyloxy)-2,3-dihydro-2-(4-methoxyphenyl)-5-(2-(methylamino)ethyl)-1,5-benzothiazepin-4(5H)-one;AKOS030242881;SCHEMBL12592499;1,5-BENZOTHIAZEPIN-4(5H)-ONE, 3-(ACETYLOXY)-2,3-DIHYDRO-2-(4-METHOXYPHENYL)-5-(2-(METHYLAMINO)ETHYL)-, (2S-CIS)-;Q27280692;(2S,3S)-2-(4-METHOXYPHENYL)-5-(2-(METHYLAMINO) ETHYL)-4-OXO-2,3,4,5-TETRAHYDRO-1,5-BENZOTHIAZEPIN-3-YL ACETATE;Cis-2-(4-methoxyphenyl)-5-(2-(methylamino)ethyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate;1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-2,3-dihydro-2-(4-methoxyphenyl)-5-(2-(methylamino)ethyl)-, cis-;DTXSID60873797;GLXC-02968;(2S,3S)-2-(4-Methoxyphenyl)-5-(2-(methylamino)ethyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate;85100-17-0;UNII-IF0841K5LK;CHEMBL3350581;

标识符

InChIKey:
YOMLDISQSWWYOT-UXHICEINSA-N
Inchi:
1S/C21H24N2O4S/c1-14(24)27-19-20(15-8-10-16(26-3)11-9-15)28-18-7-5-4-6-17(18)23(21(19)25)13-12-22-2/h4-11,19-20,22H,12-13H2,1-3H3/t19-,20+/m1/s1
SMILES:
O([C@H]1C(=O)N(CCNC)C2C=CC=CC=2S[C@H]1C1C=CC(OC)=CC=1)C(=O)C

氮位N-脱甲基盐酸地尔硫卓(86408-45-9)物化性质

实验特性

  • LogP : 4.28420
  • PSA : 93.17000

计算特性

  • 精确分子量 : 436.12200
  • 氢键供体数量 : 1
  • 氢键受体数量 : 6
  • 可旋转化学键数量 : 7
  • 同位素质量 : 400.14567842g/mol
  • 重原子数量 : 28
  • 复杂度 : 539
  • 同位素原子数量 : 0
  • 确定原子立构中心数量 : 2
  • 不确定原子立构中心数量 : 0
  • 确定化学键立构中心数量 : 0
  • 不确定化学键立构中心数量 : 0
  • 共价键单元数量 : 1
  • 疏水参数计算参考值(XlogP) : 2.6
  • 拓扑分子极性表面积 : 93.2Ų

氮位N-脱甲基盐酸地尔硫卓(86408-45-9)推荐厂家 更多厂家(4)

氮位N-脱甲基盐酸地尔硫卓(86408-45-9)合成路线

合成路线:1 步
反应条件:
参考文献:
Optical control of L-type Ca2+ channels using a diltiazem photoswitch
Fehrentz, Timm; et al, Nature Chemical Biology, 2018, 14(8), 764-767
合成路线:1 步
反应条件:
参考文献:
Optical control of L-type Ca2+ channels using a diltiazem photoswitch
Fehrentz, Timm; et al, Nature Chemical Biology, 2018, 14(8), 764-767
合成路线:1 步
反应条件:
参考文献:
A P450 fusion library of heme domains from Rhodococcus jostii RHA1 and its evaluation for the biotransformation of drug molecules
Kulig, Justyna K.; et al, Bioorganic & Medicinal Chemistry, 2015, 23(17), 5603-5609
合成路线:2 步
反应条件:
参考文献:
Optical control of L-type Ca2+ channels using a diltiazem photoswitch
Fehrentz, Timm; et al, Nature Chemical Biology, 2018, 14(8), 764-767
合成路线:1 步
反应条件:
参考文献:
High-resolution mass spectrometry elucidates metabonate (false metabolite) formation from alkylamine drugs during in vitro metabolite profiling
Barbara, Joanna E.; et al, Drug Metabolism & Disposition, 2012, 40(10), 1966-1975

氮位N-脱甲基盐酸地尔硫卓(86408-45-9)相关文献